Skip to content

Calcium Channel Splice Variant Expression in Cardiovascular Disease and Aging

Calcium Channel Splice Variant Expression in Cardiovascular Disease and Aging

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00251615
Enrollment
18
Registered
2005-11-10
Start date
2012-08-31
Completion date
2012-08-31
Last updated
2012-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Keywords

vascular surgery, vascular aging, arterial aging, surgical tissue, Aging

Brief summary

The purpose of this study is to learn what changes in blood vessel contraction may occur as a result of a disease of the vessel that requires surgery. The study will examine the calcium channels present in the vessels being operated on, and the genes that may alter blood vessel function. Possible variation in these genes may change the kind of calcium channels present in blood vessels.

Detailed description

The goal of this study is to learn more about how blood vessels function and the mechanism that causes them to contract. The study will investigate the natural history of diseased blood vessel tissue and the calcium channels in the muscle part of the blood vessel. The study will also examine how genetics influences cardiovascular disease and its causes and treatments. Patients scheduled for vascular surgery will be approached to participate in this study. During surgery, tissue fragments of diseased and marginal tissue will be obtained. A blood sample will be obtained at either the time of surgery or consent and genomic DNA will be extracted.

Interventions

None listed

Sponsors

National Institute on Aging (NIA)
Lead SponsorNIH

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ages 21 and older * Scheduled for vascular surgery

Exclusion criteria

* Unwillingness to be subjected to diagnostic and/or therapeutic procedures that are deemed not necessary for clinical management * Volunteers deemed too fragile to participate in the study by the principal investigator (PI) or the attending physician * Inability to obtain informed consent from either the volunteer or the responsible party (durable power of attorney \[DPA\]) for the volunteer, with the volunteer's assent

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026